Bicycle Therapeutics plc (BCYC) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 4, 2022 6:59 AM EDT- Continued clinical progress across pipeline, including dosing of the first patient in expansion cohorts of Phase I/II study of BT5528
- Expansion of Genentech exclusive strategic collaboration, triggering a $10 million payment to Bicycle in Q3
- Cash and cash equivalents of $372.8 million as of June 30, 2022, excludes $9.8 million UK R&D tax credit received in July and Genentech payment; expected financial runway into 2025
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and... More
